ICU Medical, Inc.

What they do

ICU develops, manufactures and sells medical products for infusion therapy, vascular access and vital care, including ambulatory, syringe and large-volume IV pumps with safety software; dedicated and non-dedicated IV sets; needlefree connectors such as Clave, Tego and Neutron; peripheral IV catheters; and closed system transfer devices like ChemoLock and ChemoClave. It sells primarily to acute care hospitals, wholesalers, ambulatory clinics and alternate site facilities such as home health and long-term care. The company was founded in 1984 and expanded through the Hospira Infusion Systems acquisition in 2017, Pursuit Vascular in 2019 and Smiths Medical in 2022. Sterile IV solutions are now offered on behalf of the Otsuka ICU Medical joint venture rather than manufactured and owned directly.

Revenue drivers

• Consumables — Includes Infusion Therapy, Oncology, Vascular Access and Tracheostomy products. Generated $289.3 million in Q2 2026, up $16.2 million year over year, the largest product line.
• Infusion Systems — Pumps, safety software and related systems. Q2 2026 revenue was $189.0 million, up $21.3 million year over year, and management said results were ahead of expectations for this line.
• Vital Care — Respiratory, anesthesia, patient monitoring and temperature management products, plus contract manufacturing and distribution of IV Solutions for the joint venture. Q2 2026 revenue fell $34.6 million to $73.4 million because the IV Solutions business was divested on May 1, 2025.
• IV Solutions joint venture distribution — ICU retained a 40% interest in Otsuka ICU Medical LLC after selling 60% to Otsuka Pharmaceutical Factory America, and sells and distributes the joint venture's products under commercial, services and license agreements.

Recent performance

Second quarter 2026 GAAP revenue was $551.7 million, up 1% from $548.9 million a year earlier, while non-GAAP organic revenue rose 6% excluding the IV Solutions divestiture and foreign currency. GAAP gross margin improved to 43% from 38%, and GAAP net income was $19.1 million, or $0.76 per diluted share, versus $35.3 million and $1.43 in the prior-year quarter. Adjusted diluted EPS was $2.37 versus $2.10, and adjusted EBITDA was $110.0 million versus $100.3 million. First half 2026 revenue was $1,081.9 million, down $71.7 million year over year, reflecting the loss of divested IV Solutions revenue. Full-year 2025 revenue was $2.23 billion with net income of $732,000 and operating cash flow of $179.8 million.

Strategy

Management is running the business around three reportable product lines - Consumables, Infusion Systems and Vital Care - after divesting the IV Solutions operations into a joint venture with Otsuka in May 2025. The company still sells and distributes joint venture IV Solutions products under commercial, services and license agreements, keeping a commercial link without owning the manufacturing assets. CEO Vivek Jain highlighted second quarter results ahead of expectations for Infusion Systems and in line with expectations elsewhere. Cost reduction and restructuring efforts are cited among the company's stated priorities and risk factors, alongside continued product development investment.

Risks

• FDA warning letter — A 2025 FDA warning letter concerns modifications to the cleared MedFusion Model 4000 syringe infusion pump and CADD Solis VIP ambulatory infusion pump that could impact continued commercial activity.
• Intense competition and GPO contracting — The infusion products market is intensely competitive, and ICU may fail to obtain or maintain contract positions with major group purchasing organizations and integrated delivery networks.
• Tariffs and trade policy — Significant changes in U.S. trade or tax policy that restrict imports or raise tariffs, particularly for Mexico and Costa Rica, are called out as risks.
• Supplier and manufacturing concentration — The company depends on single and limited source third-party suppliers and faces risks from manufacturing facility damage or supply chain disruption.

Outlook

For fiscal year 2026, ICU raised its GAAP net income guidance to $73 million to $83 million from $26 million to $44 million, and GAAP diluted EPS to $2.89 to $3.29 from $1.03 to $1.74. Adjusted EBITDA guidance was raised to $415 million to $435 million from $400 million to $430 million. Adjusted diluted EPS guidance was raised to $8.60 to $9.00 from $7.75 to $8.45.